Neurohumoral prediction of left-ventricular morphologic response to β-blockade with metoprolol in chronic left-ventricular systolic heart failure

European Journal of Heart Failure

Volumn 4, Issue 5, 2002, Pages 635-646

  Groenning, Bjoern A ^a   Nilsson, Jens C ^b   Hildebrandt, Per R ^a   Kjaer, Andreas ^c,d   Fritz Hansen, Thomas ^b   Larsson, Henrik B W ^b   Sondergaard, Lars ^a,b  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

Beta blockers; Heart failure; Left ventricle; Magnetic resonance imaging; Neurohormones; Remodelling

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALDOSTERONE; ANGIOTENSIN II ANTAGONIST; ANTILIPEMIC AGENT; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; LOOP DIURETIC AGENT; METOPROLOL; NEUROHORMONE; NORADRENALIN; PLACEBO; RENIN;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA RENIN ACTIVITY; PREDICTION; PRIORITY JOURNAL; SYSTOLE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL FACTORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHRONIC DISEASE; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HEART VENTRICLES; HORMONES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROTRANSMITTER AGENTS; PREDICTIVE VALUE OF TESTS; RENIN; ROC CURVE; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0036802849     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00038-7     Document Type: Article

References (36)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
3. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
4. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial, Lancet 353 (1999) 9-13.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet 353 (1999) 2001-2007.
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
8. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HBW, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;35:2072-80.
9. Nagel E, Underwood R, Pennell D, et al. New developments in non-invasive cardiac imaging: Critical assessment of the clinical role of cardiac magnetic resonance imaging. Eur Heart J 1998;19:1286-93.
10. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). The International Steering Committee. Am J Cardiol 1997;80:54J-58J.
11. Guyton AC. Seventh Ed. Textbook of Medical Physiology. Philadelphia: Saunders, 1986. p. 848
12. Yamaoka O, Yabe T, Okada M, et al. Evaluation of left ventricular mass: Comparison of ultrafast computed tomography, magnetic resonance imaging, and contrast left ventriculography. Am Heart J 1993;126:1372-9.
13. Mogelvang J, Stokholm KH, Saunamaki K, et al. Assessment of left ventricular volumes by magnetic resonance in comparison with radionuclide angiography, contrast angiography and echocardiography. Eur Heart J 1992;13:1677-83.
14. Ben-Jonathan N, Porter JC. A sensitive radioenzymatic assay for dopamine, norepinephrine, and epinephrine in plasma and tissue. Endocrinology 1976;98:1497-507.
15. Poulsen K, Jorgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974;39:816-25.
16. Schutten HJ, Johannessen AC, Torp-Pedersen C, Sander-Jensen K, Bie P, Warberg J. Central venous pressure - A physiological stimulus for secretion of atrial natriuretic peptide in humans? Acta Physiol Scand 1987;131:265-72.
17. Kjaer A, Knigge U, Warberg J. Involvement of oxytocin in histamine- and stress-induced ACTH and prolactin secretion. Neuroendocrinology 1995;61:704-13.
18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
19. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000;2:271-8.
20. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
21. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
22. Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993;341:1105-9.
23. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53.
24. Luchner A, Burnett JCJ, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
25. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
26. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HBW, Hildebrandt PR. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001;3:699-708.
27. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JCJ. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988;62:191-5.
28. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI40-VI48.
29. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998;19:1552-63.
30. Witte K, Thackray S, Clark AL, Cooklin M, Cleland JG. Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART. Eur J Heart Fail 2000;2:455-60.
31. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999;99:786-92.
32. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
33. Luchner A, Burnett JCJ, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study. J Am Coll Cardiol 1998;32:1839-44.
34. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
35. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758-65.
36. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.